{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:18:28Z","timestamp":1792451908423,"version":"4.5.0"},"reference-count":30,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"American Cancer Society Mentored Research Scholar","award":["MRSG-15-063-01-TBG"],"award-info":[{"award-number":["MRSG-15-063-01-TBG"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["KL2-TR001879"],"award-info":[{"award-number":["KL2-TR001879"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and the Grading System for Adrenal Pheochromocytoma and Paraganglioma (GAPP) are scoring systems to predict metastatic potential in pheochromocytomas (PCC) and paragangliomas (PGLs). The goal of this study is to assess PASS and GAPP as metastatic predictors and to correlate with survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The cohort included PCC\/PGL with \u22655 years of follow-up or known metastases. Surgical pathology slides were rereviewed. PASS and GAPP scores were assigned. Univariable and multivariable logistic regression, Kaplan\u2013Meier survival analysis, and Cox proportional hazards were performed to assess recurrence-free survival (RFS) and disease-specific survival (DSS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 143 subjects, 106 tumors were PCC and 37 were PGL. Metastases developed in 24%. The median PASS score was 6.5 (interquartile range [IQR]: 4.0-8.0) and median GAPP score was 3.0 (IQR: 2.0-4.0). Interrater reliability was low\u2013moderate for PASS (intraclass correlation coefficient [ICC]: 0.6082) and good for GAPP (ICC 0.7921). Older age (OR: 0.969, P\u2005=\u2005.0170) was associated with longer RFS. SDHB germline pathogenic variant (OR: 8.205, P\u2005=\u2005.0049), extra-adrenal tumor (OR: 6.357, P\u2005&amp;lt;\u2005.0001), Ki-67 index 1% to 3% (OR: 4.810, P\u2005=\u2005.0477), and higher GAPP score (OR: 1.537, P\u2005=\u2005.0047) were associated with shorter RFS. PASS score was not associated with RFS (P\u2005=\u2005.1779). On Cox regression, a GAPP score in the moderately differentiated range was significantly associated with disease recurrence (HR: 3.367, P\u2005=\u2005.0184) compared with well-differentiated score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Higher GAPP scores were associated with aggressive PCC\/PGL. PASS score was not associated with metastases and demonstrated significant interobserver variability. Scoring systems for predicting metastatic PCC\/PGL may be improved by incorporation of histopathology, clinical data, and germline and somatic tumor markers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa608","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T19:32:22Z","timestamp":1599075142000},"page":"e4661-e4670","source":"Crossref","is-referenced-by-count":94,"title":["Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3786-3638","authenticated-orcid":false,"given":"Heather","family":"Wachtel","sequence":"first","affiliation":[{"name":"Hospital of the University of Pennsylvania, Department of Surgery, Division of Endocrine and Oncologic, Surgery, Philadelphia, Pennsylvania"},{"name":"The Abramson Cancer Center, Philadelphia, Pennsylvania"},{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Hutchens","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra","family":"Baraban","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Montone","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubair","family":"Baloch","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"LiVolsi","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Krumeich","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania, Department of Surgery, Division of Endocrine and Oncologic, Surgery, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas L","family":"Fraker","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania, Department of Surgery, Division of Endocrine and Oncologic, Surgery, Philadelphia, Pennsylvania"},{"name":"The Abramson Cancer Center, Philadelphia, Pennsylvania"},{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L","family":"Nathanson","sequence":"additional","affiliation":[{"name":"The Abramson Cancer Center, Philadelphia, Pennsylvania"},{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Hospital of the University of Pennsylvania, Division of Translational Medicine and Human Genetics, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie L","family":"Cohen","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Hospital of the University of Pennsylvania, Department of Medicine, Division of Renal, Electrolytes and Hypertension, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Fishbein","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine, Department of Medicine, Division of Endocrinology, Metabolism and Diabetes and the Division of Biomedical Informatics and Personalized Medicine, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"issue":"3","key":"2021122106255300400_CIT0001","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021122106255300400_CIT0002","doi-asserted-by":"crossref","first-page":"T41","DOI":"10.1530\/ERC-19-0435","article-title":"Hereditary endocrine tumours: current state-of-the-art and research opportunities: metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop","volume":"27","author":"Dahia","year":"2020","journal-title":"Endocr Relat Cancer."},{"issue":"3","key":"2021122106255300400_CIT0003","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1677\/ERC-07-0074","article-title":"The diagnosis and management of malignant phaeochromocytoma and paraganglioma","volume":"14","author":"Chrisoulidou","year":"2007","journal-title":"Endocr Relat Cancer."},{"issue":"5","key":"2021122106255300400_CIT0004","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/s-0031-1299707","article-title":"Metastatic pheochromocytoma and paraganglioma: focus on therapeutics","volume":"44","author":"Plouin","year":"2012","journal-title":"Horm Metab Res."},{"issue":"8","key":"2021122106255300400_CIT0005","doi-asserted-by":"crossref","first-page":"L51","DOI":"10.1530\/ERC-17-0086","article-title":"SDHB mutation carriers with malignant pheochromocytoma respond better to CVD","volume":"24","author":"Fishbein","year":"2017","journal-title":"Endocr Relat Cancer."},{"issue":"5","key":"2021122106255300400_CIT0006","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/cen.13434","article-title":"Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"87","author":"Hamidi","year":"2017","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"6","key":"2021122106255300400_CIT0007","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021122106255300400_CIT0008","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer."},{"issue":"5","key":"2021122106255300400_CIT0009","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1245\/s10434-013-2942-5","article-title":"Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing","volume":"20","author":"Fishbein","year":"2013","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"2021122106255300400_CIT0010","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am J Surg Pathol."},{"issue":"4","key":"2021122106255300400_CIT0011","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e318190d12e","article-title":"Observer variation in the application of the pheochromocytoma of the adrenal gland scaled score","volume":"33","author":"Wu","year":"2009","journal-title":"Am J Surg Pathol."},{"issue":"3","key":"2021122106255300400_CIT0012","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr Relat Cancer."},{"key":"2021122106255300400_CIT0013","volume-title":"WHO Classification of Tumours of Endocrine Organs"},{"issue":"1","key":"2021122106255300400_CIT0014","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep."},{"issue":"11","key":"2021122106255300400_CIT0015","doi-asserted-by":"crossref","first-page":"e0187398","DOI":"10.1371\/journal.pone.0187398","article-title":"Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma","volume":"12","author":"Koh","year":"2017","journal-title":"PLoS One."},{"issue":"4","key":"2021122106255300400_CIT0016","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4103\/picr.PICR_123_17","article-title":"Common pitfalls in statistical analysis: measures of agreement","volume":"8","author":"Ranganathan","year":"2017","journal-title":"Perspect Clin Res."},{"issue":"2","key":"2021122106255300400_CIT0017","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/cancers11020225","article-title":"The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas-a meta-analysis and systematic review of the literature","volume":"11","author":"Stenman","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"6","key":"2021122106255300400_CIT0018","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrendo.2014.41","article-title":"Neuroendocrine cancer. Closing the GAPP on predicting metastases","volume":"10","author":"Eisenhofer","year":"2014","journal-title":"Nat Rev Endocrinol."},{"issue":"4","key":"2021122106255300400_CIT0019","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12022-013-9269-4","article-title":"Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas","volume":"24","author":"Castelblanco","year":"2013","journal-title":"Endocr Pathol."},{"issue":"6","key":"2021122106255300400_CIT0020","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.humpath.2009.12.005","article-title":"Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes","volume":"41","author":"Gill","year":"2010","journal-title":"Hum Pathol."},{"issue":"2","key":"2021122106255300400_CIT0021","doi-asserted-by":"crossref","first-page":"E287","DOI":"10.1210\/jc.2014-1870","article-title":"SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma\/paraganglioma","volume":"100","author":"Menara","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021122106255300400_CIT0022","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/modpathol.2015.41","article-title":"SDHB\/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T)","volume":"28","author":"Papathomas","year":"2015","journal-title":"Mod Pathol."},{"issue":"3","key":"2021122106255300400_CIT0023","first-page":"769","article-title":"The systems of metastatic potential prediction in pheochromocytoma and paraganglioma","volume":"10","author":"Wang","year":"2020","journal-title":"Am J Cancer Res."},{"issue":"7","key":"2021122106255300400_CIT0024","doi-asserted-by":"crossref","first-page":"E1266","DOI":"10.1210\/jc.2012-4257","article-title":"Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing","volume":"98","author":"Crona","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"26","key":"2021122106255300400_CIT0025","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/hmg\/dds374","article-title":"Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma","volume":"21","author":"Burnichon","year":"2012","journal-title":"Hum Mol Genet."},{"issue":"20","key":"2021122106255300400_CIT0026","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1093\/hmg\/ddr324","article-title":"Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma","volume":"20","author":"Burnichon","year":"2011","journal-title":"Hum Mol Genet."},{"issue":"26","key":"2021122106255300400_CIT0027","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1093\/hmg\/dds402","article-title":"Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas","volume":"21","author":"Welander","year":"2012","journal-title":"Hum Mol Genet."},{"key":"2021122106255300400_CIT0028","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1038\/ncomms7140","article-title":"Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas","volume":"6","author":"Fishbein","year":"2015","journal-title":"Nat Commun."},{"issue":"2","key":"2021122106255300400_CIT0029","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell."},{"issue":"2","key":"2021122106255300400_CIT0030","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1158\/1078-0432.CCR-18-0139","article-title":"Telomerase activation and ATRX mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma","volume":"25","author":"Job","year":"2019","journal-title":"Clin Cancer Res."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa608\/33709127\/dgaa608.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/12\/e4661\/41829166\/dgaa608.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/12\/e4661\/41829166\/dgaa608.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T01:27:29Z","timestamp":1640050049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/12\/e4661\/5900767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,9,2]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa608","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,9,2]]}}}